Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28742005 | 0.87 | KDM4E (0.43) | KDM4ESMN1; SMN2RXFP1MAPTGLA | |
| SCHEMBL2260441 | 0.84 | KDM4E (0.47) | KDM4ESMN1; SMN2RXFP1MAPTGLA | |
| SCHEMBL23219125 | 0.83 | TBXAS1 (0.45) | KDM4ESMN1; SMN2RXFP1MAPTGLA | |
| SCHEMBL29852848 | 0.83 | TBXAS1 (0.45) | KDM4ESMN1; SMN2RXFP1MAPTGLA | |
| SCHEMBL3604567 | 0.83 | TGFBR1 (0.43) | KDM4ESMN1; SMN2RXFP1MAPTGLA | |
| SCHEMBL2265835 | 0.82 | TGFBR1 (0.43) | KDM4ESMN1; SMN2RXFP1GLAGAA | |
| SCHEMBL3595719 | 0.81 | KDM4E (0.42) | KDM4ESMN1; SMN2MAPTGLAGAA | |
| SCHEMBL20985982 | 0.81 | KDM4E (0.45) | KDM4ESMN1; SMN2RXFP1MAPTGLA | |
| SCHEMBL3595383 | 0.80 | POLB (0.46) | KDM4ESMN1; SMN2RXFP1MAPTGLA | |
| SCHEMBL2261118 | 0.78 | MAPK1 (0.49) | KDM4ESMN1; SMN2RXFP1MAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-12-01 | — | — | US | disclosed |
| US-8058425-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-11-15 | — | — | US | disclosed |
| US-8022065-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-04-23 | — | — | US | disclosed |
| US-7491716-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1483265-B1 | PURINE DERIVATIVES AS KINASE INHIBITORS | LILLY CO ELI (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY | 2005-04-28 | — | — | US | disclosed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | KDM4E 4107/4885SMN1; SMN2 2545/4885RXFP1 435/4885 |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | PNP, ADK, NME2 | KDM4E 1308/4885SMN1; SMN2 4465/4885RXFP1 2572/4885 |
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | KDM4E 1308/4885SMN1; SMN2 4465/4885RXFP1 2572/4885 |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | KDM4E 1308/4885SMN1; SMN2 4465/4885RXFP1 2572/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | KDM4E 200/4885SMN1; SMN2 3372/4885RXFP1 2455/4885 |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | KDM4E 1308/4885SMN1; SMN2 4465/4885RXFP1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.